Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIFE2: Low molecular weight heparin for recurrent miscarriage in inherited thrombophilia
2015-002357-35Phase 3Unknown
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of enoxaparin, dalteparin and tinzaparin in Congenital Thrombophilia, recurrent miscarriage (RPL) and stillbirth (2 arms), sponsored by University Hospitals Coventry and Warwickshire NHS Trust. Primary endpoint: Live birth. Status: unknown.
02
Drugs
enoxaparindalteparintinzaparin
03
Conditions
Congenital Thrombophiliarecurrent miscarriage (RPL)stillbirth
Beyond the preview
Go deeper on 2015-002357-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002357-35.